To verify the nature of viability loss induced by GPX4 inhibition, we conducted rescue experiments in ABC-DLBCL lines using ferrostatin-1 (Fer-1), a lipophilic antioxidant that suppresses ferroptosis, alongside zVAD-fmk (a pan-caspase inhibitor) and necrostatin-1s (Nec-1s, a RIPK1 inhibitor). Here, GPX4 is linked to aneurysmal bone cyst.